Physician
Vangorder, Mark
Vangorder, Mark was paid $3.90M by Medicaid between Jan 2018 and Dec 2024, across 128 billing codes. Its largest line is U0002, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc — 9.7% of everything it billed.
33Billing provider infoVANGORDER, MARK
OLYMPIA FIELDS, IL 60461
OLYMPIA FIELDS, IL 60461
33aNPI1053304956assigned 08/25/2005
33bProvider typeAnatomic Pathology & Clinical Pathology Physician
28Total paid$3.90M
24GClaims605,106
24DCodes billed128
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Anatomic Pathology & Clinical Pathology Physician providers in Illinois
Rank by total paid#16 of 398
Median peer was paid$66K
This provider vs. median59×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 39,340 | $208K | |
| 2019 | 77,659 | $399K | |
| 2020 | 112,448 | $681K | |
| 2021 | 102,699 | $679K | |
| 2022 | 99,045 | $718K | |
| 2023 | 95,525 | $708K | |
| 2024incomplete | 78,390 | $507K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 9.7% | 13,897 | 11,471 | $379K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 8.9% | 9,763 | 9,112 | $347K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 8.2% | 13,849 | 11,474 | $318K |
| 80053 | Comprehensive metabolic panel | 6.6% | 51,112 | 35,006 | $258K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 5.3% | 72,541 | 48,482 | $207K |
| 80048 | Basic metabolic panel (calcium, ionized) | 5.1% | 47,472 | 20,939 | $200K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 4.1% | 3,353 | 2,921 | $158K |
| 83735 | 3.1% | 33,977 | 16,709 | $122K | |
| 84484 | 3.0% | 23,252 | 16,665 | $117K | |
| 85027 | 2.5% | 32,942 | 12,793 | $96K | |
| 87634 | 2.2% | 3,393 | 3,243 | $86K | |
| 87641 | 2.0% | 3,623 | 3,129 | $79K |
116 more codes
| 87040 | 2.0% | 6,652 | $79K | |
| 88307 | 1.7% | 1,180 | $67K | |
| 82803 | 1.7% | 8,418 | $65K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.7% | 2,991 | $64K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.6% | 2,805 | $63K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.6% | 2,802 | $63K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.5% | 1,079 | $58K |
| 83880 | 1.5% | 5,647 | $58K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.3% | 4,031 | $50K |
| 83605 | 1.3% | 8,816 | $49K | |
| 83690 | 1.3% | 14,643 | $49K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.2% | 370 | $48K |
| 81025 | 1.2% | 21,409 | $47K | |
| 84443 | Thyroid stimulating hormone (TSH) | 1.2% | 5,768 | $47K |
| 85730 | 1.0% | 10,794 | $39K | |
| 87430 | <1% | 4,432 | $34K | |
| 81001 | <1% | 22,260 | $31K | |
| 85610 | <1% | 15,462 | $30K | |
| 86780 | <1% | 3,091 | $26K | |
| 86850 | <1% | 8,477 | $25K | |
| 86901 | <1% | 10,999 | $24K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,280 | $24K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,494 | $23K |
| 84105 | <1% | 11,983 | $20K | |
| 85379 | <1% | 4,903 | $18K | |
| 86900 | <1% | 9,543 | $16K | |
| 87806 | <1% | 1,637 | $16K | |
| 84702 | <1% | 3,460 | $15K | |
| 82728 | <1% | 3,896 | $15K | |
| 87631 | <1% | 288 | $15K | |
| 87186 | <1% | 2,146 | $14K | |
| 82077 | <1% | 1,382 | $14K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,477 | $14K |
| 82607 | <1% | 2,329 | $14K | |
| 84703 | <1% | 3,766 | $13K | |
| 82805 | <1% | 658 | $13K | |
| 80076 | <1% | 4,179 | $13K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 589 | $12K |
| 87449 | <1% | 1,544 | $12K | |
| 82746 | <1% | 2,082 | $12K | |
| 82550 | <1% | 4,704 | $11K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 105 | $10K |
| 81003 | <1% | 8,769 | $10K | |
| 84145 | <1% | 2,125 | $9K | |
| 88248 | <1% | 748 | $8K | |
| 80202 | <1% | 1,116 | $8K | |
| 83550 | <1% | 1,939 | $8K | |
| 82570 | <1% | 3,151 | $8K | |
| 80061 | Lipid panel | <1% | 2,995 | $8K |
| 83540 | <1% | 2,351 | $7K | |
| 86738 | <1% | 737 | $7K | |
| 86769 | <1% | 176 | $7K | |
| 84439 | <1% | 1,630 | $7K | |
| 87081 | <1% | 2,163 | $7K | |
| 86920 | <1% | 1,695 | $6K | |
| 86140 | <1% | 2,449 | $6K | |
| 87420 | <1% | 674 | $5K | |
| 87210 | <1% | 2,174 | $5K | |
| 80074 | <1% | 266 | $5K | |
| 85651 | <1% | 1,921 | $4K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 230 | $4K |
| 84300 | <1% | 1,749 | $4K | |
| 87205 | <1% | 2,021 | $4K | |
| 82436 | <1% | 1,564 | $4K | |
| 87340 | <1% | 526 | $3K | |
| 84133 | <1% | 1,538 | $3K | |
| 84100 | <1% | 1,408 | $3K | |
| 84156 | <1% | 2,358 | $3K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 434 | $3K |
| 82140 | <1% | 587 | $3K | |
| 87070 | <1% | 747 | $2K | |
| 87486 | <1% | 104 | $2K | |
| 87581 | <1% | 104 | $2K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 102 | $2K |
| 82010 | <1% | 1,008 | $2K | |
| 85045 | <1% | 1,614 | $2K | |
| 80177 | <1% | 420 | $2K | |
| 83930 | <1% | 769 | $2K | |
| 85007 | <1% | 1,032 | $2K | |
| 87899 | <1% | 366 | $2K | |
| 80164 | <1% | 403 | $2K | |
| 87077 | <1% | 961 | $2K | |
| 83615 | <1% | 795 | $2K | |
| 86880 | <1% | 615 | $2K | |
| 84550 | <1% | 1,095 | $2K | |
| 82261 | <1% | 191 | $2K | |
| 83520 | <1% | 219 | $1K | |
| 82247 | <1% | 646 | $1K | |
| 85060 | <1% | 281 | $1K | |
| 83516 | <1% | 223 | $1K | |
| 82330 | <1% | 135 | $921.84 | |
| 83935 | <1% | 392 | $913.21 | |
| 85384 | <1% | 332 | $910.47 | |
| 83498 | <1% | 191 | $854.99 | |
| 86141 | <1% | 101 | $811.15 | |
| 86706 | <1% | 111 | $735.66 | |
| 85652 | <1% | 570 | $730.49 | |
| 87088 | <1% | 105 | $662.60 | |
| 82128 | <1% | 190 | $489.60 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 27 | $472.50 |
| 82016 | <1% | 188 | $464.10 | |
| 82776 | <1% | 190 | $461.84 | |
| 86480 | <1% | 17 | $416.50 | |
| 88304 | <1% | 26 | $358.52 | |
| 82248 | <1% | 188 | $315.72 | |
| 84478 | <1% | 121 | $195.36 | |
| 88342 | <1% | 18 | $195.16 | |
| 84466 | <1% | 42 | $184.38 | |
| 80069 | <1% | 39 | $163.04 | |
| 86308 | <1% | 55 | $131.52 | |
| 86762 | <1% | 27 | $109.46 | |
| 87324 | <1% | 13 | $94.75 | |
| 82043 | <1% | 43 | $84.71 | |
| 85520 | <1% | 21 | $82.53 | |
| 83655 | <1% | 13 | $77.09 | |
| 88720 | <1% | 17 | $37.83 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.